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Breast cancer is caused by a variety of environmental and genetic factors that 
influence cell growth and survival. Changes in the level or function of cell cycle 
regulatory proteins are often associated with breast cancer.  Low expression of the cell 
cycle inhibitor, p27Kip1, is associated with aggressive breast tumors.  Clinical 
observations have inspired studies to analyze p27 as a potential target for signal 
transduction pathways in cancer cells. The stability of p27 determines it’s ability to 
regulate the cell cycle, and changes in transcription and translation of p27 are less 
influential. The regulation of the cellular localization of p27 by signal transduction 
pathways has become a focus of recent research. This study attempts to clarify how Akt 
regulates p27 localization and stability, and what implications this data may have on 
tumor growth and metastasis. Cells were transfected with MryAkt plasmid to artificially 
activate Akt. Immunoflorescence and cell fractionation results verified that MryAkt 
causes cytoplasmic retention of p27 in MCF-7 breast cancer cells. Labeling experiments 
with 35S methionine demonstrated that MryAkt causes  nascent p27 to accumulate in the 
cytoplasm .Metabolic pulse chase labeling and cyclohexamide experiments also 
determined that p27 was stabilized by MryAkt.  Degradation in the nuclear and 
cytoplasmic compartments was unaffected by Akt, which supports the hypothesis that 
MryAkt effects only p27 localization, and the stabilization of p27 by Akt is a result of its 
cytoplasmic retention. Lastly, the mitogen estradiol has similar effects on p27 as MryAkt, 
proving that estrogen can influence p27 through the Akt pathway. 
 v
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I. Literature Review 
The Cell Cycle  
The eukaryotic cell cycle is regulated by cyclin dependent kinases (Cdks). Cdks 
are activated when proteins called cyclins bind to them and form complexes. In each cell 
cycle, cyclins are regulated by a series of synthesis and degradative possesses, and 
changes in cyclin levels result in the assembly and activation of the cyclin /Cdk 
complexes that trigger the cell cycle events.  G1 phase of the cell cycle is regulated by 
cyclin D and Cdk 4/6, G1/S is initiated by cyclin E/Cdk2, S phase is regulated by cyclin 
A/Cdk2, and m phase or mitosis is controlled by cyclin B/Cdk1 (Cdc2).  Cdks are 
inactive when cyclins are not bound. Cdks have their active site blocked by the t-loop 
region of the protein. When cyclins bind this causes the t-loop to move away from the 
active site, then a cyclin activating kinase (CAK) phosphorylates the complex at a 
threonine residue in the t-loop. This fully activates the enzyme complex by changing the 
shape of the t-loop an improving the ability of the enzyme to bind substrate. A cell cycle 
inhibitor protein (CKI), p27kip1 (p27) or p21cip 1 (p21), can bind to the cyclin- Cdk 
complex and distort the active site of the Cdk. Also they can insert into the ATP binding 
site. p27 and p21 form trimeric complexes with cyclin E or A Cdk2 complexes to 
inactivate their enzyme activity. Previously it was thought that at physiological 
concentrations, p21 and p27 promote formation of active D cyclin-Cdk4/6 complexes but 
at higher concentrations they inhibit Cdk4/6 activity.  Now recent studies have shown 
that cyclin D complexes form independently of p21 and p27 (1) (2).  The function of 
cyclinD/Cdk4/6 is to sequester p27 away from cyclin E/Cdk2, then cyclin E/Cdk2 and 
 2 
 
cyclinA/Cdk2 can be activated and initiate GB1 B/S phase transition. Also Cdk4 is 
responsible for phosphorylating Retinoblastoma protein (explained below) (3).  
INK4 Proteins 
Members of the INK4 protein family can inhibit Cdk4/6, prevent them from 
binding to cyclin D, which prevents the G1/S transition of the cell cycle. This family 
consists of P16INK4a, P15INK4b, P18INK4c and p19INK4d which share a common 
structural motif, the ankyrin repeats, that have pairs of anti-parallel α-helices stacked side 
by side and connected by a series of intervening hairpin motifs (4). These domains of the 
INK4 proteins are responsible for binding to the non-catalytic side of Cdk4 and Cdk6 
(opposite to the cyclin D binding site) and this binding induces and allosteric change in 
the Cdks which alters the binding of D type cyclins and reduces their affinity for ATP. 
Furthermore, this prevention of cyclin D complex formation redistributes the inhibitors 
p27 and p21 to cyclin E/Cdk2 complexes, which further inhibits G B1 B/S phase transition.  
The E2F Family and Retinoblastoma Protein 
E2F and Retinoblastoma protein (Rb) are important contributors to the GB1 B/S phase 
transition of the cell cycle. pRb is a tumor suppressor gene that is absent or mutated in at 
least one- third of human tumors, including familial inactivating tumors that are 
associated with the pediatric eye tumor retinoblastoma. Rb is a member of a family of 
proteins called the pocket proteins that also includes p107 and p130 (5). Rb binds to the 
transcription factor E2F in the large pocket region (amino acids 395-876) and suppresses 
E2F activation. The small pocket region of Rb (379-792), binds to the LXCXE region of 
 3 
 
E2F, and viral oncoproteins can also bind to this region and interfere with Rb/E2F 
binding (6). Figure 1 shows an illustration of Rb and E2F-1 function in the cell cycle.  
The E2F protein belongs to a family of similar proteins divided into groups based 
on sequence homology: E2F-1, 2 and 3 in one subgroup and E2F-4 and 5 in the second 
group. A third subgroup exists containing E2F-6, which suppresses transcription 
independent of pocket protein binding. This protein has almost no homology outside the 
DNA binding and dimerization, and has truncated C and N terminal groups. Group one 
E2F proteins possess an N-terminal cyclinA/Cdk2 binding domain and a canonical basic 
nuclear localization signal (NLS).  E2F-1, 2&3 preferentially associate with Rb, while 
E2F-4&5 associates with p107 and p130 (6).  
E2F proteins are transcription factors that exist as heterodimers with one member 
of the E2F protein family and one member of the DRTF1 (DP) family. The six members 
of the E2F family can form different combinations of heterodimers with the two members 
of the DP family. E2F was identified as a cellular factor required for the adenovirus early 
region 1A transforming protein to mediate transcriptional activation of the viral E2A 
promoter. DP was discovered because its DNA binding activity decreased during 
differentiation of F9 embryonic carcinoma stem cells. Collectively, DP and E2F were 
shown to have similar DNA binding sequences, and now the activity of this heterodimer 
is referred to as simply E2F (7).   
G1/S Transition of The Cell Cycle  
        In G1 phase of the cell cycle, cyclin DCcdk4/6 complexes initiate Rb 





Adopted from C. Stevens La Thangue/Archives of Biochem and biophysics 412(2003)157-169
Figure 1: Regulation of E2F activity
Rb suppresses E2F activity until it is phosphorylated by the cyclin D/cdk4
complex. Free E2F becomes transcriptionally active and interacts with the
cofactors p300/CBP. The pRB/E2F complex represses transcription 
by recruiting proteins HDAC, MTase, PCF and SWI/SNF that alter




Rb on additional sites.  The hyperphosphorylation of Rb in late G1 disrupts its association 
with E2F and allows this protein to initiate the transcription of genes necessary for DNA 
synthesis. Once free from inhibition by Rb, E2F drives cells into S phase as it regulates 
transcription factors that initiate the G1 to S transition. Repression by the Rb-E2F 
complex is required to force G1 arrest by anti-proliferative signals. Subsequent activation 
of Cyclin A and B Cdks maintains Rb in the hyperphosphorylated form until the cells exit 
mitosis and Rb is returned to it’s hypophosphorylated state in the next G1 (8). A 
representation of the cell cycle and important cell cycle regulators and their inhibitors is 
shown in figure 2. 
Cdc2 and Cdk2 Regulation 
  Activation of Cdk2 is the key regulatory event at the G1/S phase transition. In 
addition to the CKIs, Cdk2 is also regulated and phosphorylated on threonine 160 by a 
heterotrimer consisting of Cdk7, cyclin H and Mat1 kinase (9). Another kinase, Wee1, 
phosphorylates Cdk2 on tyrosine 15 and deactivates it (10), (11).  The phosphatase, 
Cdc25A, dephosphorylates tyrosine 15 and restores Cdk2 activity (12), (13). 
 In early G2, Cdc2 becomes the predominant Cdk and this continues through M phase. 
Cdc2 is also deactivated by phosphorylation on tyrosine 15 by Wee1 and threonine 14 by 
a membrane associated kinase Myt1.  Myt1 kinase inhibits Cdc2 both by its inhibitory 
phosphorylation and by sequestering Cdc2 at the cell membrane away from the nuclear 




Figure 2: The mammalian cell cycle. (A) Arrows indicate the relative         
increase of the cyclin levels at different phases of the cell cycle. G1=gap 1, 
S=synthesis, G2=gap2, m=mitosis, CDK=cyclin dependent kinase, 
Rb=retinoblastoma protein. (B) Cell cycle proteins and their inhibitors. TGF-





p27 and Cancer 
The cell cycle inhibitor, p27, has become an important focus of study in many 
types of cancer research. p27 could be and important protein target for cancer therapy. 
This is evident because the amount of p27 protein has been shown to be a possible 
prognostic marker in human neoplasms such as breast, lung, esophageal, and colorectal 
carcinomas. Low expression or increased degradation of p27 protein occurs in many 
human tumors, and this strongly correlates with tumor progression and poor prognosis 
(8). p27 knockout mice display gigantism with multi-organ hyperplasia, suggesting that 
p27 limits the replicative capacity of differentiating cells. Also p27-/- mice develop 
pituitary tumors, and have high susceptibility to carcinogen and radiation induced 
tumorigenesis. The mammary glands of p27 (-/-) mice are underdeveloped compared to 
wild type, but the mammary epithelium of p27 (+/-) mice is hyperproliferative and 
susceptible to oncogene induced tumorigenesis (14), (15). Much of p27 in cells is 
controlled post transcriptionally, i.e. p27 protein levels are controlled by ubiquitin-
mediated proteolyses at the G1/S borders, although p27 can be controlled 
transcriptionally as well.  
p27 Degradation and The SCFSKP2 Complex 
The ubiquitination and subsequent degradation of nuclear p27 is carried out by a 
multi enzyme complex consisting of E1 ubiquitin activating enzyme, E2 ubiquitin 
conjugating enzyme, and E3 ubiquitin ligase (16), (17). This complex consists of adaptor 
molecules that ligate proteins to chains of a small peptide called ubiquitin, which allows 
the protein to be recognized and degraded by the proteosome (18). This mechanism is a 
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Skp2 protein dependent cyclin E/Cdk2 mediated degradation pathway (19).  Ubiquitin 
dependent proteolysis of p27 is regulated by phosphorylation on threonine 187 by cyclin 
E/Cdk2 in late G1. Phosphorylation on threonine 187 allows recognition of p27 by the 
SCF type E3 ligase complex (20).  Polyubiquitinated p27 is then targeted to the 26s 
proteosome and degraded. The complex of proteins required for p27 degradation called 
the SCFSKP2 complex, contains Skp1, Skp2, Cul1, Cks1, and Rbx/Roc1 and is 
responsible for recognizing phosphorylated p27 and catalyzing ubiquitination (21), (22) .  
Part of the SCF complex, the protein Skp2, was originally identified as a protein 
associated with S phase promoting kinase Cdk2/cyclin A, and Skp2 activation is required 
for S phase entry (23). Skp2 is a member of a diverse family of proteins that share 
common sequence motif called the F box. Skp2 associates with peptides derived from 
the extreme carboxyl terminus of p27, and full-length p27.  This association is 
responsible for recruiting p27 to the SCF complex. Skp1 directly binds to the F-Box 
motif and mediates assembly of the SCFSKP2 ubiquitin ligase complex (24).  The center 
of the complex is Cullin (Cul1) which interacts with all three subunits and serves as a 
scaffold.  Rbx/Roc1 binds to Cul1 and acts as an essential component of the E3 ubiquitin 
ligase (25). Rbx /Roc1 recruits the E2 enzyme, CDC34/UBC3, to the complex. The E2 
and E1 enzymes transfer ubiquitin to the substrate (p27), and mark it for degradation 
(18). Also the complex requires an accessory protein called Cks-1 that binds Skp2. The 
two amino acid residues in Cks-1 that are required for interaction with Skp2 and 
ubiquitination of p27 have been identified (26). The paper by Wang et al shows that Cks-
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1 binds to the carboxyl terminal region of Skp2 and that the amino acid Asp331 is 
essential for binding (27).  An illustration of this complex and cell cycle regulators is 
shown in figure 3.  
Studies have shown that p27 phosphorylated on serine 10 is more stable than the 
unphosphorylatable S10A mutant protein. p27 is phosphorylated on serine 10 by the His 
kinase (28).  Phosphorylation on serine 10 accounts for about 70% of the total 
phosphorylation of p27 and is increased in G0/G1 phase of the cell cycle (29). In Skp2 -\- 
lymphocytes, p27 has been shown to behave similarly to p27 in wild type cells at the 
G0/G1 transition of the cell cycle, while proteolysis at the S/G2 phases is impaired (30). 
This suggests that p27 also degrades by a Skp2 independent process in G0/G1 (31).     
Current evidence suggests that in fact p27 is degraded by a Skp2 independent 
ubiquitination pathway in the cytoplasm, and a Skp2 dependent ubiquitination pathway 
in the nucleus (30).                                                                          
p27 and The MCF-7 Cell Cycle 
 Translational controls, and proteolysis in MCF-7 breast cancer cells and other 
cell types regulate p27 levels.  p27 protein levels are decreased as cells progress from G1 
to S phase (32). p27 levels are elevated in G0 phase of the MCF-7 cell cycle. In early G1 
after mitogen stimulation, cyclin D/cdk4 complex sequesters p27.  In mid G1 (8-10 
hours), the levels of p27 begin to decline prior to an increase in Skp2 (3). This is thought 
to be due to nonspecific degradation in the cytoplasm, because p27 is exported to the 
cytoplasm by phosphorylation on serine 10 (and subsequent mitogen stimulation) and this 
process is independent of Skp2. In late G1, the SCFSKP2 ubiquitin ligase complex 
Adopted from http:www.med.nyu.edu/cgi-bin
Figure 3. The SCF Skp2 degradation complex
p27 is phosphorylated on threonine 187 by cdk2/cyclin E at G1/S. p27 





further degrades nuclear p27 (12-18 hours) (33).  After S phase (12 hrs) the level of p27 
begins to increase. 
Estrogen and MCF-7 Cells 
p27 protein levels are regulated by 17β estradiol (estrogen or EB2 B) in many cell 
types. Estrogen is a potent mitogen for estrogen receptor positive MCF-7 Cells. Estrogen 
stimulates proliferation by increasing synthesis of cyclin D and Skp2 proteins, while 
decreasing p27 protein levels.  Also estrogen increases the activity of cyclin D/Cdk 4 
complexes, which sequester p27 thereby increasing Cdk2 kinase activity (3). The 
classical steroidal action of estrogen is via two genetically different nuclear receptors, 
nERα and nERβ (34). These receptors have divergent functions and cellular actions. 17β 
estradiol, which has a higher affinity for ERα, transfuses the membrane and binds the ER 
in the cytoplasm. The receptors undergo conformational changes, form heterodimers or 
homodimers, and translocate to the nucleus where they activate transcription factors and 
initiate the synthesis of proteins. ERα seems to be a more potent activator than ERβ, and 
when both receptors are expressed ERβ can decrease ERα activity (34).  The same ER 
ligand complex is not recognized similarly in all cells, which accounts for the diversity of 
ER function. This is partly due to the two classes of co-regulators of ERs. Co-activators 
nucleate protein complexes at gene promoters to enhance transcription. Co-repressors 
recruit proteins that lead to the suppression of transcriptional activation (35). Activated 
ERs can initiate transcription by binding to estrogen response elements (EREs) within 
promoters. Also they can indirectly increase transcription through the activation of 
transcription factors (TF) like AP1, or SP1, or they can suppress transcription by 
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inhibiting TF like Nf-kB. This genomic action of estrogen via the nuclear receptors is 
characterized by a latency of onset of 2-8 hours (36).  
Now estrogen is known to have non-genomic effects, which are described by a 
short response time, insensitivity to inhibitors of transcription and translation, and 
different properties than nuclear receptors i.e. different antagonists. These rapid effects 
appear to originate from plasma membrane receptors located in the caveolae and to date, 
a membrane ER has been partially characterized. Theoretically, through binding to 
membrane receptors, this steroid can activate tyrosine kinase receptors like EGFR and G 
protein coupled receptors (38), which activate signal pathways including the 
Ras/Raf/Mek/Erk (39), (40) pathway and the Ras PI3 K/Akt pathway (39) (41).  
p27 Localization  
 It has recently been noted that p27 cytoplasmic and nuclear localization may be 
important in MCF-7 breast cancer cells and other cell types.  The transport of proteins 
from the nucleus to the cytoplasm is mediated by a nuclear export signal (NES), which 
consists of a conserved set of leucine residues. Mutations of these residues disrupt this 
export process. The protein, Crm-1 (part of the Importin B related nuclear transport 
receptors) associates with the NES and mediates export of proteins including p27 (42). 
When p27 is phosphorylated on this site and mitogen is available, Crm-1 dependent 
export occurs and p27 is transported to the cytoplasm (33). Leptomycin B (LMB) can 
inhibit this export process by binding to Crm-1 and preventing it from interacting with 
the NES of substrate proteins (42).   
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p27 interaction with the nuclear pore protein NUP50/NPAP60 may have a role in 
nuclear import (43) (44). A nuclear localization signal (NLS) on p27 has been identified 
and may have other mediators (45), (46). The phosphorylated p27 interacts with a 
protein called Jab1 and cotransfections with these two genes showed increased 
proteolysis of p27 in certain cell types.  The observation that LMB inhibited Jab-1 
mediated export suggests that a CRM-1 dependent nuclear export mechanism influences 
degradation of p27 (47). CRM-1 and the GTPase Ran regulate nuclear import and 
export. In the nucleus, Ran-bound GDP exchanges for ran GTP (by the guanine 
exchange factor protein (GEF) RCC1) and binds export cargo destined for the 
cytoplasm. In the cytoplasm, Ran GTP dissociates the complex (48). In the paper by 
Connor et al, the nuclear export of p27 is regulated by Crm-1/Ran GTP binding and is 
time, temperature and energy dependent and a NES is required (49). Lastly, a recent 
study has demonstrated that Crm-1 dependent export of p27 requires its phosphorylation 
at serine 10 and stimulation of the Ras/Raf/Mek/Erk pathway by mitogens (33). 
 PI3 Kinase and Akt/PKB 
         p27 localization is influenced by the PI3 Kinase Akt pathway in certain cell types 
(52), (53), (54). There are three PKB/Akt genes in metazoans which yield the protein 
products PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3. The three genes are regulated 
similarly and have similar structures; they contain an amino-terminal pleckstrin 
homology domain and require phosphorylation for activation. Akt belongs to the ACG 
family of protein kinases (protein kinase A, protein kinase C, and protein kinase G). This 
group requires phosphorylation of a flexible peptide t loop near the catalytic core of the 
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kinase domain for activation (50). Akt is activated by PI3 kinase. PI3 kinase is a 
heterodimeric complex consisting of an 85 kDa regulatory subunit and a 110 kDa 
catalytic subunit. There are eight mammalian PI3 kinases and they are categorized into 
three classes (I, II, and III) (51).  A summary of these classes is shown in table one. 
PI3 kinase is activated by receptor tyrosine kinases or G protein coupled 
receptors. When localized to the membrane via its regulatory 85 kDA subunit, (an SH2 
domain containing subunit) it associates with tyrosine phosphorylated receptors or 
adaptors.  Then the catalytic subunit is responsible for PI3 kinase catalyzing the 
phosphorylation of inositol phospholipids at the three position of the inositol ring to 
generate the lipids phosphatidylinositol 3, 4 bisphosphate PI (3,4) p2 and 
phosphatidlylinositol 3,4,5 triphosphate. PI (3,4,5,) p3. As the levels of these lipids rise, 
pleckstrin homology domain containing proteins like AKT and PDK1 are recruited to the 
membrane. PDK1 phosphorylates and activates AKT by phosphorylating it on threonine 
308, which causes autophosphorylation of serine 473 (or phosphorylation by another 
kinase PDK2 but this is still being debated). PI3K is inactivated by phosphatases like 
PTEN (phosphatase and tensin homologue deleted from chromosome ten) that removes 
the phosphate from the three position on the inositol ring (50).  Some downstream targets 
of PI3 kinase are shown in figure 4. 
p27 Localization and Akt 
Recently studies have demonstrated that p27 localization is important in cell cycle 
arrest in cancer cells. p27 is mislocalized to the cytoplasm in ovarian, breast and thyroid 




































modifying the localization of p27 by it’s phosphorylation at threonine 157 on p27, 
preventing nuclear import and making p27 mostly cytoplasmic (52). Furthermore, when 
PKB/Akt phosphorylates p27 at threonine157, it impairs nuclear import of p27 and 
opposes p27 mediated GB1 Barrest (53)  (54).  The sequence requirement for nuclear 
localization and growth inhibition of p27 was determined in Hela cells. The sequence is 
amino acids 153-168 and residues K168 and I169 were critical for nuclear localization 
(55). Another study by Sekinoto et al has also demonstrated that Akt phosphorylates p27 
at threonine 157 and that this prevents nuclear import of the protein. This group located 
the nuclear localization signal of p27 to the c-terminal end of the protein specifically the 
classical bipartite-type basic region plus amino acids 152-168. This group attempts to 
show that the scaffold protein 14-3-3 competes with the importin protein α5 for binding 
to threonine 157 phosphorylated p27, and prevents it from entering the nucleus.  In the 
absence of 14-3-3, p27 is imported via this protein (56).   
Ras Proteins 
Ras proteins have been shown to influence p27 localization through the 
Ras/Raf/Mek/Erk pathway (33). Also Ras is involved in the activation of PI3 Kinase 
through G protein coupled receptors (50). Ras proteins are members of a large Ras super 
family of structurally and functionally conserved GTPases.   The carboxyl terminus of all 
Ras proteins has a highly conserved distinct sequence, a caax motif and a hypervariable 
domain that promotes association with the plasma membrane. Differences in the 
membrane localization of Ras might correlate with the specificity of different proteins in 
this family.  Mammalian cells contain at least three Ras proto-oncogenes: H-Ras, K-Ras 
 18 
 
and N-Ras.  H-Ras and K-Ras were first discovered as viral (v-Ras) oncoproteins of the 
Harvey and Kirsten murine sarcoma viruses that were capable of cellular transformation. 
H-Ras is highly expressed in the skin and skeletal muscles, K-Ras in the colon and 
thymus, and N-Ras in male germinal tissue and thymus. The K-Ras gene is mutated in 
non-small lung cancer (33%), colorectal cancer (44%) and pancreas cancer (90%). N-Ras 
is mutated in melanoma (13%), liver cancer  (30%), and myelogenous leukemia (30%). 
H-Ras is mutated in bladder cancer  (10%), and kidney cancer (10%) (57).  
Ras Effectors 
There are three main Ras effectors in cells, RAF kinase, RAL-GEFs and PI3-K, 
which bind the same region of Ras-GTP the 32-40 amino acid domain.  Ras-GTP can 
bind and activate the catalytic subunit of PI3 kinase, which can then activate downstream 
targets like Akt. Ras is often required to transmit signals from receptor tyrosine kinases 
(57). If Ras function is inhibited by an anti-Ras antibody or a dominant- negative mutant 
Ras, cell proliferation or differentiation responses normally induced by the activated RTK 
are inhibited. If constitutively active Ras is transfected into some cells, cell proliferation 
or differentiation is increased. Ras has been shown to activate separate signaling 
pathways including the Raf/Mek/Erk/ pathway and the PI3K pathway. It has been 
demonstrated that in cells continuously exposed to growth factors, that Ras is needed in 
two phases of the G0 to S interval (58). This is evident by studies conducted with anti-Ras 
antibody or dominant negative Ras mutants that can be introduced to cells several hours 
after serum stimulation and still block S phase. Also Ras antibodies blocked the cell cycle 
when given before serum stimulation (59). Several researchers found that Erk is active 
 19 
 
only during the initial part of prolonged Ras activity and that active Erk is not detectable 
during the mid to late phases of G1. This might suggest that the Erk pathway is not 
responsible for this part of the cell cycle (60).  This observation raises the possibility that 
Ras targets different effectors for the various phases of the cell cycle.  PI3k was 
discovered to be active during G0/G1 transition and mid to late G1. Inhibiting PI3k 
activity during G0/G1 had no effect on cell cycle progression but did affect S phase entry 
when it was inhibited in mid and late G1 (61). Lastly, Ras has been observed to be active 
throughout the cell cycle but only stimulated cyclin D1 and promotes cell cycle 
progression during G2 phase (58). It has previously been shown that activation of the 
Ras/Raf/Mek/Erk pathway in breast cancer cells causes p27 to be exported to the 
cytoplasm (33) and that constitutive activation of this pathway prevents arrest by 
antiestrogens. Mitogen stimulation of quiescent cells causes two peaks of Ras activation, 
one on entry into G1 phase and associated with Raf pathway, and the second associated 
with PI3 kinase pathway at mid G1 phase. It has been shown that activated Ras is 
essential for up regulation of cyclin D1 and down regulation of p27 (57). A summary of 
Ras targets is shown in figure 5.




II. HYPOTHESIS AND RATIONALE 
The study of the cell cycle inhibitor p27 and its function in cancer cells has become a 
complicated story.  p27 knockout mice studies have provided insight into the necessity of 
this protein, but have also raised many questions, primarily, what is the main function of 
p27 in breast cancer and other cancer types.  Not only is the stability of p27 important, 
but also studies have recently emerged showing that the cellular location of p27 may be 
involved in cancer development.  The hypothesis that p27 has divergent functions based 
on its location in the cell may explain large differences in the phenotypes of p27-/- and 
p27+/- mice. Although recent studies have sought to discover the signal pathways that 
influence p27 localization, there remains much to be clarified.  
 The mammary tissue of p27 heterozygote mice is hyperproliferative and 
susceptible to tumors in some studies.  Translational mechanisms rather than 
transcriptional processes more often regulate p27 levels in the mammary gland, and many 
studies have suggested that signal transduction pathways like PI3 kinase/Akt and 
Ras/Raf/Mek/Erk have an effect on both p27 localization and degradation. The 
hypotheses to be tested in this study are 1) Active Akt effects the localization of p27 in 
MCF-7 breast cancer cells 2) active Akt effects the stability of p27 in these cells 3) active 
Akt effects the stability of p27 differently in the nucleus versus the cytoplasm 4) estrogen 






UIII. MATERIALS AND METHODS 
Reagents and Antibodies 
Cell culture media and antibiotics, 17β estradiol (E2), fetal bovine serum (FBS), 
anti-flag M2-agarose affinity gel, monoclonal (M2) and rabbit polyclonal anti-flag 
antibodies were from Sigma Chemical Company (St. Louis, MO). ICI 182,780 is 
supplied by Dr. Alan Wakeling at Zeneca Pharmaceuticals (Alderly Park, Chashire, UK). 
Protein A/G beads were from Santa Cruz (California). Monoclonal anti-actin was from 
Roche Applied Science (Indianapolis, IN). Tubulin and fluorochrome-labeled goat anti 
mouse secondary antibody 488 were from Molecular Probes (Eugene, Oregon). E2F-1 
antibody was from Neomarkers/Labvision (Freemont, Ca). Tran  [P35 PS] label was from 
ICN (Irvine, CA).  
Cell Culture and Transfections 
MCF-7 cells were a gift from R.P Shiu and maintained in Dulbecco’s Modified 
Eagles Medium with 2.5% FBS and penacilin/streptamicin. Cells were growth arrested 
by 2 days of culture in phenol red free Dulbecco’s Modified Eagles Medium with .1% 
FBS and 20 nM ICI 182, 780. Chemical stock solutions were prepared in ethanol (ICI 
182,780, and 17β estradiol), and control cultures received equal amounts of solvents as 
vehicle controls where appropriate. Plasmid vectors for MryAkt were from (Antonio 
Cuadrado). M. Cobb provided vectors for constitutively active ERK kinase. Plasmids for 
flag-p27 (wild-type and T157A mutant) were from Naoya Fuijita. C..M. Counter 
provided the Ras V12S35 plasmid. Transfections were carried out using LipofectAMINE 
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PLUS transfection reagent from Invitrogen (Carlsbad, CA), using .2 µg of flag-p27 and .4 
µg of other vectors or .6 µg of total DNA to cells seeded in 6 well plates. 
Cell Lysis, Western Blotting and Immunoprecipitations 
Cells were collected with PBS/EDTA in microcentrifuge tubes and centrifuged 
for 5 minutes at 2.5 RPM. Cell pellets were lysed in ice-cold .5% Nonident P-40, and 
triton X-100 buffer with 1 mM EDTA, 1mM NaOV4, 10 mM NaF, 10 µg/ml leupeptin, 1 
mM phenylmethylsulfonyl fluoride, with centrifugation at 11, 000 G for 10 minutes to 
remove cellular debris. Protein samples were equalized using the Bradford Assay from 
BIORAD (Hercules, CA) and read with the spectrophotometer machine. Western blotting 
samples were prepared with an equal amount of protein (50-100µg) and 25% of the 
sample consisted of Lammeli sample buffer. Equal volumes (20-25 µl) of protein samples 
were loaded onto a 12% polyacrylamide gel. The gel was run for 1.5 hours then 
transferred to nitrocellulose, washed with TBST then blocked in .5%casein/TBST for 
thirty minutes. The blot was incubated with flag-p27 rabbit polyclonal antibody diluted 
1:1000 in blocking buffer overnight. After primary antibody, the blot was washed three 
times with TBST then incubated with anti-rabbit secondary antibody in blocking buffer 
for one hour. Then blot was washed three times for five minutes with TBST and ECL 
chemilumenecent reagent from Amersham (Buckinghamshire, England) was added to the 
blot for five minutes before blot was exposed to Kodak or Fuji film. Analysis of protein 
bands on the films was determined with Kodak 3.5 imaging software, and graphed using 
Prism Graph pad software 4.0.  Immunoprecipitations were performed with 2 µl/sample 
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of Flag M2 affinity agarose (50% slurry in PBS) with 15 µl A/G beads per sample in 
addition to 150 µl of lysis buffer plus equal amounts of protein lysate.  
Cellular Localization of p27 by Fractionation 
Nuclear/cytoplasmic cell fractionation was carried out by lysis in hypotonic buffer 
with .02% digitonin. Samples were then vortexed lightly once per minute for five 
minutes, then centrifuged at 1000G for five minutes to separate the nuclear fraction from 
the cytoplasmic fraction. After centrifugation, the cytoplasmic fraction was removed and 
placed into new microcentrifuge tubes then centrifuged at 10,000G for ten minutes to 
remove cellular debris. Nuclear fractions were lysed with hypotonic buffer then 
centrifuged for five minutes at 1000 G, then the supernatant was discarded and the 
remaining nuclear fraction was freeze thawed then lysed in 500 mM NaCl and ice-cold 
NP-40 lysis buffer as described previously.  
Cellular Localization of p27 by Immunoflorescence 
MCF-7 cells grown on glass cover slips were transfected with the flag-p27 
plasmid with MryAkt, pcDNA3, dnAkt, or RasV12S35 plasmids. After forty hours, cells 
were washed with PBS then fixed with 3% paraformaldehyde for twenty minutes. After 
fixation, cells were washed with PBS then permeablized with .5% Triton in 1% BSA for 
five minutes. After permeablization, cells were washed three times with PBS then 
blocked with blocking buffer (1% goat serum +1%BSA) for thirty minutes. Then slides 
were incubated with primary antibody (anti-flag M2 monoclonal .2 µg/ml) overnight in 
4oC. After primary antibody cells were washed in PBS three times for five minutes then 
incubated for two hours with secondary fluorochrome-labeled goat anti- mouse antibody. 
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The cover slips were then mounted on slides using DAKO mounting medium, and 
nuclear versus nuclear/cytoplasmic flag-p27 was counted visually on an Olympus IMT-2 
fluorescent microscope. For quantification, a minimum of three hundred cells were 
counted for each determination and results were derived from at least three independent 
experiments.  
Pulse and Pulse Chase Analysis of p27  
MCF-7 cells in 6-well plates were transfected with flag-p27 or flag-T157Ap27 
(mutant p27) with either of the following, MryAkt, pcDNA3, or dnAkt. 40 hours post 
transfection, methione/cysteine minus medium was replaced as the cell culture medium 
for 30 minutes. The cells were then labeled with 50 µCi/well of [35S] methionine added to 
medium (without methionine or cysteine) for one hour. For the chase, monolayers were 
washed once with fresh complete medium and incubated for the indicated times then 
collected for fractionation or lysis. For the pulse, 50 µCi/well of 35S methionine was 
added to cells on 6 well plates and at the indicated times, cells were washed with fresh 
complete medium then collected for fractionation or lysis. Flag-p27 was 
immunoprecipitated from nuclear/cytoplasmic lysates or whole cell lysates as explained 
above.  An equal amount of 35 S methionine labeled lysates was calculated from 
quantitative values obtained from TCA precipitation of 2 µl of each sample analyzed by a 
scintillation counter 
p27 Stability Determined by Cyclohexamide Experiments 
MCF-7 cells in 6 well plates were cotransfected with flag-p27 and other indicated 
plasmids. 40 hours post transfection, cells were treated with 10 µg/ml cyclohexamide for 
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the indicated time points then cells were collected and lysed as explained previously and 
analyzed by western blotting.  
Statistical Analyases 





IV. RESULTS  
MryAkt Keeps p27 Mostly Cytoplasmic 
We examined the role of activated Akt in the nuclear/cytoplasmic localization of 
p27. In order to activate the Akt pathway exclusively, MCF-7 breast cancer cells were 
transfected with MryAkt plasmid and also flag-p27 plasmid. p27 localization was 
enumerated by immunostaining with anti-flag antibodies.  MryAkt expression in the cells 
causes flag-p27 to be significantly (p<. 003) more cytoplasmic (figure 6) compared to 
control cells expressing flag-p27 and control plasmid pcDNA3 (compare bars one and 
two from left). The amount of cytoplasmic p27 is also significantly decreased (p< .004 
compare bars three and four from right to second bar from right) in cells expressing flag-
p27 and the dominant negative inactive Akt (dnAkt) plasmid in growing medium with 
serum, or with estrogen. Estrogen is a potent mitogen for MCF-7 cells, and a proven 
activator of the PI3 Kinase/Akt pathway, and the Ras/Raf/Mek/Erk pathway (39), (40), 
(41). Cells expressing dnAkt then treated with estrogen showed less cytoplasmic p27, 
compared to cells expressing flag-p27 and MryAkt. The dnAkt results suggest that 
growth factors like serum or estrogen cannot effect p27 localization when the Akt 
pathway is inhibited.  Furthermore, previous studies (52), (53), (54) have demonstrated 
that, the cytoplasmic retention of p27 is theoretically due to phosphorylation of p27 at 
threonine 157 by activated Akt, which prevents nuclear translocation of p27. In order to 
determine if this phosphorylation site is required for the cytoplasmic retention of p27, 
cells were transfected with MryAkt and with flag-T157Ap27 plasmid, in which the Akt 
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Figure 6: MryAkt increases cytoplasmic p27. 
(A) MCF-7 cells were transfected with flag-p27 and one of the 
following cotransfectants: pcDNA3, MryAkt, dnAkt (in complete 
medium with serum (S)), dnAkt with E2, or T157Ap27 with 
MryAkt. After 40 hours of growth arrest in medium with .2% FBS 
and 20 nM ICI, the localization of flag-p27 was analyzed by 
immunostaining with anti-Flag antibodies. The proportion of cells 
exhibiting  cytoplasmic p27 was enumerated. The values for the 
experiment are devrived from three independent experiments and 
are givein as the mean + S.D. Statistical analysis was based on a 
two-tailed t test. # #, significantly different from controls at 





phosphorylated by active Akt.  In figure 6 (far right bar on graph), when cells 
express the T157Ap27, the amount of nuclear p27 is significantly (p< .004) reduced to 
control levels. T157Ap27 is significantly less cytoplasmic than wild type flag-p27 in cells 
coexpressing MryAkt (compare far right bar with second bar from left).  
 Fractionation of MCF-7 cells transfected with MryAkt plasmid and flag-p27 
plasmid verified that active Akt does increase cytoplasmic p27 and decrease the amount 
of nuclear p27 protein  (figure 7, compare lanes one and three, two and four) compared to 
cells transfected with flag-p27 and pcDNA3. Cells expressing flag-p27 plasmid and 
dnAkt plasmid show an equal distribution of p27 in both compartments (lanes 5 and 6). 
In agreement with the immunoflorescent experiment data, cells expressing MryAkt and 
flag-T157Ap27 show less cytoplasmic flag-p27 than wild type p27 transfected cells with 
MryAkt (compare lanes 3&4 of panel A with lanes 3&4 panel B).  
The Ras/Raf /Mek/Erk pathway has previously been shown to cause rapid export 
of p27 from the nucleus when this pathway is activated. The Ras/Raf/ Mek/ Erk pathway 
causes export of p27 by a Crm-1 dependent pathway when it is phosphorylated on Serine 
10 (33).  In figure 7B, constitutively active Ras and Mek plasmids transfected into cells 
with flag-p27 showed increased cytoplasmic p27 as expected.  
MryAkt Prevents Newly Synthesized p27 from Entering the Nucleus.  
In figures 6&7, p27 increases in the cytoplasm when Akt is activated. We wanted 
to further investigate whether Akt affected the localization of nascent p27 as well.  MCF-
7 cells were transfected with flag-p27 plasmid with MryAkt plasmid, or flag-p27 with 
control plasmid. After 40 hours, the transfected cells were pulsed with 35S methionine for 
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Figure 7: MryAkt, Ras, and Mek increase cytoplasmic p27. 
(A) Active Akt increased cytoplasmic p27 compared to controls. 
MCF-7 cells were transfected with flag-p27 and one of the 
following cotransfectants: (A)pcDNA3, MryAkt, dnAkt, or (B) 
T157Ap27 with MryAkt (C) Constitutively active Ras and Mek. 
After 40 hours of growth arrest in medium with .2% FBS and 20
nM ICI, the localization of flag-p27 was analyzed by western 
blotting and staining with anti-flag antibody. E2F protein is a 
nuclear compartment control. (B) T157Ap27 is more nuclear 
compared to wildtype (compare lanes 4 with lane 4 of panel A). 
(C) Ras and Mek increase cytoplamic p27, Compare lanes 1and 3 




two, four and six hours. At the completion of each time, cells were collected and 
fractionated. The quantitative results based on densitometry from three experiments are 
presented as graphs in figures 8A and B, which display the percentage of p27 in each 
cellular compartment at the indicated times.  Figure 8C shows a representative 
autoradiograph.  Figure 8A indicates that MryAkt decreased the amount of nascent 
nuclear flag-p27 by six hours. In contrast, flag-p27 in control plasmid expressing cells 
shows p27 increasing in the nucleus. The cytoplasmic compartment reflects the opposite; 
MryAkt causes cytoplasmic flag-p27 to increase (figure 8B), while control cells show a 
decrease in cytoplasmic p27. This data agrees with that obtained in figures 6 and 7.   
The data obtained in figure 8 shows that flag-p27 increases in the cytoplasm in 
cells were Akt is activated. Whether Akt is affecting nuclear export or import of nascent 
flag-p27 is still in question. In order to clarify this issue, cells were transfected with flag-
T157Ap27 (the phosphorylation mutant of p27) and MryAkt, or dnAkt or pcDNA3. If 
MryAkt is affecting import of flag-p27, then this mutant should behave opposite to 
wildtype flag-p27 i.e. not be retained in the cytoplasm. Figure 9A demonstrates that flag-
T157Ap27 increases in the nucleus in contrast to wildtype flag-p27 (figure 8A) in Akt 
activated cells. In addition, flag-T157Ap27 decreases in the cytoplasm in figure 9B when 
coexpressed with MryAkt.  DnAkt and pcDNA3 transfected cells coexpressing flag-
T157Ap27 show this protein decreasing in the nuclear compartment in figure 9A, and 
slightly increasing in the cytoplasm in figure 9B. The cause of this phenomenon remains 
unclear and requires further investigation.
Figure 8: MryAkt increases nascent cytoplasmic p27
(C) Cells were transfected with flag-p27 plus MryAkt (bottom) or pcDNA3 
(top) plasmids.  After 40 hours the localization of new p27 was determined 
by pulse analysis with  35S methionine. At the indicated times cells were 
collected and fractionated.  The nuclear and cytoplasmic lysates were 
immunoprecitpitated with anti-flag antibody and resolved by SDS-PAGE. 
(A,B)The quantitative results based on  densitometry are presented as 
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Figure 9: MryAkt increases T157A in the nucleus
(C) Cells were transfected with flag-T157Ap27 plasmid and pcDNA3 or 
dnAkt plasmid. Cells were pulsed with 35S methionine and at 3 and 6 hours, 
cells were collected and fractionated. Flag-T157Ap27 was 
immunoprecipitated and from cytoplasmic and nuclear lysates. 
Immunoprecipitates were resolved by SDS-PAGE. (A,B) The quantitative 
results based on densitometry are presented as a graph  (A) % nuclear 





Estrogen Increases Nascent Cytoplasmic p27 by Activating Akt 
 Estrogen activates the PI3 Kinase/Akt pathway in MCF-7 cells (41), and is a 
potent mitogen; estrogen decreases p27 levels, and increases cyclin D protein (3). In this 
study we wanted to investigate the role estrogen plays in the localization of p27.  Cells 
were transfected with flag-p27, or flagT157Ap27 and pcDNA3.  Also some cells were 
transfected with dnAkt and flag-p27. Transfected cells were labeled with 35S methionine 
as described above and fractionated. Estrogen was added to the cells at time of pulse 
where indicated in figure 10A. Estrogen caused a slight increase of cytoplasmic flag-p27 
by 6 hours, compared to control cells with flag-p27 and pcDNA3 without estrogen 
treatment. DnAkt with estrogen showed decreased cytoplasmic flag-p27 (figure 10A 
green line). This suggests that overexpressing inactive Akt (dnAkt) can inhibit the ability 
of estrogen to influence p27 localization, and that estrogen must regulate p27 through this 
pathway.  
 Surprisingly, cells transfected with flag-T157Ap27 and estrogens behave similar 
to wildtype flag-p27 with estrogen (figure 10A&B).  T17Ap27 accumulates in the 
cytoplasm similar to wildtype (figure 10A compare black to red line on graph). Also 
T157Ap27 decreased in the nucleus (figure 10B compare black and red line). Previously 
it has been shown that estrogen can cause export of serine 10 phosphorylated p27 from 
the nucleus when mitogen is added via the Erk pathway.  If T157Ap27 is entering the 
nucleus, then adding estrogen can increase its export.In estrogen treated cells, wildtype 
flag-p27 was prevented from entering the nucleus by activating Akt, which 
phosphorylates p27 on threonine 157.
Figure 10: Estrogen increases nascent cytoplasmic p27 through Akt
(C,D) Cells were transfected with flag-p27 and  pcDNA3, or dnAkt, or 
T157Ap27 and pcDNA3. After 40 hours of  growth arrest estrogen (E2) was 
added to the indicated samples simultaneously with 35S methionine. At the 
indicated times cells were collected and fractionated. Fractionated lysates
were immunoprecipitated with anti-flag antibody. Immunoprecipitates were 
resolved by SDS-PAGE. (A) The quantitative results based on densitometry 
are presented as a graph % cytoplasmic flag-p27 or flag-T157A, (B) % 
nuclear flag-p27 or flag-T157Ap27 (C,D) Representative blot of one 
experiment. C=cytoplasmic fraction, N=nuclear fraction
35
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MryAkt Stabilizes Flag-p27 
 The stability or degradation rate of p27 is important for proper MCF-7 cell cycle 
function. Interfering with p27 stability can alter the cell cycle in these cells and other cell 
types.  Since p27 levels are often affected by signal transduction pathways in the cell, we 
also wanted to investigate whether activating the Akt pathway could affected the stability 
of flag-p27 in MCF-7 cells.  
Analysis of p27 degradation by activated Akt was conducted by transfecting cells 
with flag-p27 and MryAkt plasmids. After growth arrest, the cells were treated with 
cyclohexamide (10 µg/ml) for the indicated times for two, five and eight hours. The cells 
were collected and western blotted with anti-flag antibody. This experiment was repeated 
three times with comparative results. Figure 11B displays the western blot from cells 
expressing MryAkt and flag-p27 (left panel), or pcDNA3 and flag-p27 (right panel). The 
quantitative results based on densitometry are represented as a graph in figure 11A.  
Figure 11A&B show that MryAkt expressing cells have stabilized flag-p27 protein, 
compared to cells expressing flag-p27 and pcDNA3 which show a steady decrease in 
flag-p27 levels over time.  MryAkt expression stabilizes p27 protein but has no effect on 
actin levels. 
 In order to determine if the Akt phosphorylation mutant of p27, T157Ap27, has 
any role in stabilization of p27, cells were transfected with flag-T157Ap27 plasmid with 
MryAkt plasmid. As shown in figure 11C, and in the graph in figure 11A, cells 
expressing flag-T157Ap27 were equally stable compared to wild type. This result 
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Figure 11: p27 degradation following cyclohexamide treatment
(B) Cells were transfected with MryAkt and flag-p27 plasmids or pcDNA3 and 
flag-p27, or (C) T157Ap27 and MryAkt. (B&C) After 40 hours, cells were 
treated with 10 ug/ul cyclohexamide for the indicated times prior to lysis. 
Protein lysates were analyzed by western blotting with anti-flag antibody. 
CHD=cyclohexamide, tx=treatment. The experiment was repeated  three times 
with comparative results (A) The quantitative results based on densitometry 









suggests that this Akt phosphorylation site has no role in the stability of p27, and is only 
important in the cellular localization of p27.  
The degradation results of flag-p27 following cyclohexamide treatment were 
verified by 35S methionine labeling pulse chase experiments.  MCF-7 cells were 
transfected with the flag-p27 with MryAkt plasmid, or pcDNA3 plasmid. Transfected 
cells were labeled with 35S methionine for one hour then chased with complete medium 
(without 35S methionine) and collected at the indicated times.   35S methionine labeled 
protein lysates were used to immunoprecipitate flag-p27. Immunoprecipitates were 
resolved by SDS-PAGE and figure 12B shows a representative autoradiograph. The 
experiment was repeated three times and the graph in figure 12A displays the quantitative 
results of those experiments.  The pulse chase labeling results are in agreement with the 
results obtained from the cyclohexamide experiments. Figure 12A shows that cells 
expressing MryAkt were able to stabilize flag-p27 protein up to eight hours, while cells 
expressing control plasmid show flag-p27 degrading over time.  
Since the mutant of p27, T157A, was stable in the presence of MryAkt in 
cyclohexamide experiments, we wanted to investigate this concept by pulse chase 
analysis also. In figure 13, cells were transfected with T157Ap27 plasmid with MryAkt 
plasmid, then subjected to pulse chase analysis and resolved as explained above. The 
autoradiograph (figure 13B) of flag-T157Ap27 and the graph in figure 13A shows this 
protein accumulating in the cells, before it degrades by eight hours.  The Akt 
phosphorylation site on p27, theoinine 157, does not seem to have a role in the 
degradation of p27, and this data suggests that this mutation might interfere with 
A.
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Figure 12: MryAkt stabilzes flag-p27 in vivo
(B) Cells were transfected with  flag-p27 and  MryAkt or pcDNA3 plasmids. 
After 40 hours, cells were labeled with 35 S methionine for 1.5 hours then chased 
with complete medium and collected at the indicated times. Cell lysates were 
immunoprecipitated with anti-flag antibody and resolved by SDS-PAGE (A) The 
quantitative results of three experiments based on densitometry are presented as a 
graph. (B) Representative autoradiograph of one experiment
40
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Figure 13: MryAkt stabilizes T157A p27
(B) Cells were transfected with  the indicated flag-T157Ap27 plasmid 
MryAkt. After 40 hours cells were pulsed with 35S methionine for one 
hour then chased for the indicated times. Lysates were immunoprecipitated
with flag antibody then resolved by SDS-PAGE.
(A) Quantitative results based on densitometry are presented




degradative mechanisms in the cell, shown by the accumulation and subsequent decrease 
of this protein in the cell.  
MryAkt Has no Effect on Cytoplasmic p27 Degradation.  
Since activated Akt stabilizes p27 protein, we sought to investigate which cellular 
compartment; the nucleus or cytoplasm, contained more stable p27.  Cells were 
transfected with flag-p27 with MryAkt or pcDNA3, then labeled with 35S methionine as 
explained previously. Cells were collected at zero, three and six hours and fractionated to 
separate the cytoplasmic compartment from the nucleus. The experiment was repeated 
two or three times and the collective quantitative densitometry results are shown by the 
graph in figure 14A.  Figure 14B displays a representative autoradiograph of one 
experiment. In figure 14, flag-p27 was immunoprecipitated from the cytoplasmic lysate. 
MryAkt expressing cells show flag-p27 degrading at a similar rate in the cytoplasm, as in 
the whole cell lysate (compare graph in figure 14A with graphs in figures 11A and 12A).  
In contrast, flag-p27 in control plasmid expressing cells degrades slower in the cytoplasm 
than in the whole cell lysate (compare pcDNA data in figures 14A to figures 11A and 
12A). This discrepancy in degradation rate for flag-p27 in pcDNA expressing cells in the 
cytoplasm compared to the whole cell lysate, could be due to the different distribution of 
p27 in the cell. When Akt is activated, there is more p27 in the cytoplasm than in control 
cells. This concept is further explained in the discussion.  The T157Ap27 mutant 
accumulates in the cytoplasm and the whole cell lysate (compare figures 14A and 13A). 
This T157A mutation may alter degradative mechanisms in the cell, resulting slower 
degradation and subsequent accumulation of this protein. 
B.
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Figure 14: MryAkt does not stabilize p27 in the cytoplasm
(B) Cells were transfected with Flag-p27 or flag-T157Ap27 plasmid 
with pcDNA3 or MryAkt plasmids. At the indicated times, Cells
were fractionated and flag-p27 was immunoprecipitated from 
cytoplasmic lysates.  Immunoprecipitates were resolved by SDS-PAGE.
(A) Quantitative results based on densitometry are presented as a 





p27 Degrades Similarly in the Nucleus in pcDNA3 and MryAkt Expressing Cells 
 We also wanted to investigate the role of activated Akt in the nuclear degradation 
of flag-p27. Cells were transfected with flag-p27 or T157Ap27 with MryAkt or pcDNA3. 
p27 degradation was analyzed by methionine labeling pulse chase experiments, and the 
cells were fractionated at three and six hours. Flag-p27 was immunoprecipitated from the 
nuclear compartment. Figure 15 shows that flag-p27 in pcDNA3 and MryAkt expressing 
cells degrades at a similar rate in the nucleus. T157Ap27 accumulates in  the nucleus in 
MryAkt expressing cells, which agrees with data in figure 14A and figure 13A.   
Estrogen Has a Similar Effect on p27 Stabilization in the Nucleus and Cytoplasm 
Since estrogen can influence the localization of p27 through the Akt pathway 
(figure 10), it was important to investigate whether estrogen has any affect on stabilizing 
p27 in the separate cellular compartments through activating Akt.  p27 degradation was 
analyzed by pulse chase analysis in cells transfected with flag-p27, T157Ap27 and dnAkt 
or pcDNA3, and all transfected cells were treated with estrogen during the chase.  Flag-
p27 was immunoprecipitated from the nuclear fraction (figure 16) or the cytoplasmic 
fraction (figure 17).  Estrogen has no effect on the stabilization of p27 in control plasmid 
or dnAkt plasmid transfected cells in the nucleus or cytoplasm (figures 16 and 17). Cells 
transfected with T157Ap27 and treated with estrogen show a similar accumulation in 
both compartments (figure 16 and figure 17).  
Mechanism of p27 Regulation by Activated Akt 
Figure 18 demonstrates the potential mechanisms of p27 regulation by Akt found 
in this study. Akt is activated in cells either artificially or by transfecting cells with 
PcDNA3MryAkt MryAkt+T157A
Flag-p27






















Time chase (hours)    0        3        6        0   3       6       0         3       6
Figure 15 : MryAkt does not stabilize p27 in the nucleus
(B) Cells were transfected with flag-p27 or T157Ap27 plasmids and 
pcDNA3 or MryAkt plasmids. After 40 hours cells were labeled with 35S 
methionine for 1.5 hours then chased with complete medium. Cells were 
collected at the indicated times and fractionated. Flag-p27 was 
immunoprecipitated from the nuclear lysate and resolved by SDS-PAGE. (A) 




























pcDNA3   dnAKT            T157A p27 
Flag-p27
Time Chase (hrs)    0        3         6       0    3        6        0    3    6         
Estrogen
Figure 16: Estrogen does not stabilize p27 in the nucleus
(A) Cells were transfected with flag-p27 or T157Ap27 with the other 
indicated plasmids. Cells were labeled with 35S methionine for 1.5 
hours then chased for 3 and 6 hours in regular medium. Estrogen (E2)  
was added during chase to medium. Cells were collected, fractionated 
and p27 was immunoprecipitated from nuclear extracts and resolved by 
SDS-PAGE. (A) Quantitative results based on densitometry are 


























Time Chase (hours)  0        3       6         0       3      6 0       3       6
Figure 17: Estrogen does not stabilize p27 in the cytoplasm
(B) Cells were transfected with flag-p27 or T157Ap27 with one of the 
other indicated plasmids. Cells were labeled with 35S methionine for 
1.5 hours then chased for 3 and 6 hours in regular medium. Estrogen 
(E2)  was added during chase to medium. Cells were collected, 
fractionated and p27 was immunoprecipitated from cytoplasmic 
extracts and analyzed by western blotting. (A) Quantitative results 
based on densitometry are represented as a graph. 
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Figure 18: Proposed mechanism of p27 regulation by Akt
Akt is activated by PI3 kinase, or artificially by MryAkt plasmid 
overexpression. PI3 kinase is activated by various receptors on the plasma 
membrane including estrogen (E2) receptors which bind E2 and 
activatemembrane receptors that activate PI3 kinase. When Akt is 
activated, it phosphorylates p27 on threonine 157 and this phosphorylation 
prevents p27 from entering the nucleus. p27 in the cytoplasm is more stable 
because degradation in the cytoplasm is slower. p27 may have cytoplasmic 
functions, like inactivation of Rho which leads to cell migration. In control 
cells were Akt in not active, p27 enters the nucleus and is degraded faster 
by the SCFskp2 protein ligase complex when it is phosphorylated on 
threonine 187 by the cyclinE/cdk2 complex. 
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MryAkt, or by treating with growth factors or mitogens (E2) that activate PI3 Kinase 
which activates Akt. When Akt is activated, it phosphorylates downstream targets like 
p27. When Akt phosphorylates nascent p27 on threonine 157, its nuclear translocation is 
prevented. Cytoplasmic p27 is more stable, due to the slower rate of degradation in the 
cytoplasm. Cytoplasmic p27 might have other functions, like the inactivation of Rho, 
which could increase cell migration. In control cells where Akt in not activated, p27 
readily enters the nucleus where it can be phosphorylated (more quickly) by the SCFskp2 
protein ligase complex, when it is phosphorylated on threonine 187 by cyclinE/cdk2 




Cdk inhibitors, like p27, are pertinent regulators of mammalian cell growth, and 
their deregulation has been linked to tumor growth and several cancers.  This study was 
conducted to investigate the proteins and signal pathways that regulate the degradation or 
localization of p27. Recently the cytoplasmic retention of p27 has become of interest. p27 
is retained in the cytoplasm in prostate, esophagus, thyroid, ovarian and breast 
carcinomas{7013}.   This study suggests that Akt decreases p27 nuclear translocation by 
phosphorylating the protein on threonine 157. This mechanism was shown by both 
microscopic analysis of the cellular localization of p27, and by cellular fractionation. 
Previous studies have shown that cytoplasmic retention of p27 by active Akt increases 
Cdk2 activity. An active Cdk2/cyclin E complex initiates S phase of the cell cycle and 
eventual cell division. Cytoplasmic p27 may have other roles besides its nuclear function 
as a Cdk2 inhibitor. A recent study by Roberts et al (62), showed that cytoplasmic p27 
has a role in cell migration by demonstrating that  p27 null mice have decreased wound 
healing, due to suppressed migration of fibroblasts. GTPases of the Rho family play a 
large role in the regulation and remodeling of the cytoskeleton, a mechanism important in 
cell migration. According to the same study, p27 increases cell migration by the 
inactivation of Rho by reducing Rho-GTP levels. Cells lacking p27 have increased 
numbers of actin stress fibers and focal adhesions, which is indicative of Rho activation. 
Increases in cell motility and mobilization has been linked to tumor metastasis and 
vascularization. In order for tumor cells to spread throughout the body, mobilization of 
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the current tumor cells must occur. Also, since tumors grow at an accelerated rate and 
quickly deplete their supply of oxygen, they must vascularize in order to survive. If p27 
plays a role in these processes, then p27’s cytoplasmic retention by Akt might be 
conducive to tumor spread, and this could be an important target for future drug therapy.  
Also this might explain the growth promoting effects of p27 in heterozygote mice (4).  
 
 Active Akt in this study was also shown to influence newly synthesized p27. The 
synthesis of new p27 was determined with pulse experiments by labeling cells with 35S 
methionine for the indicated times then collecting cells, and fractionating the nucleus 
from the cytoplasm. Over time, p27 protein in cells coexpressing MryAkt showed less 
nuclear p27. At three hours, the amount of p27 in the nucleus was similar in cells 
cotransfected with flag-p27 and either of the following: MryAkt, pcDNA3, dnAkt, or 
MryAkt and the p27 phosphorylation mutant T157A p27. By six hours, the amount of 
newly synthesized flag-p27 in the nucleus was less with active Akt present, and flag-p27 
increased in the cytoplasm. This demonstrates a novel phenomenon that MryAkt does in 
fact influence new p27, and prevent its nuclear localization. PcDNA3 showed increasing 
amounts of p27 in the nucleus by six hours. DnAkt transfected cells expressing flag-p27 
showed p27 increasing in the nucleus similar to pcDNA expressing cells, because Akt is 
inactive and not able to phosphorylate p27. T157A p27 behaves opposite to wild type 
flag-p27 in MryAkt transfected cells.  T157Ap27 enters the nucleus and behaves similar 
to control (wild type p27 coexpressing pcDNA3).  
 In this study, estrogen also decreased the percentage of newly synthesized p27 in 
the nucleus by six hours. Estrogen is a potent mitogen for MCF-7 breast cancer cells (3), 
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and also has been shown to activate the PI3K/Akt pathway, and the Ras/Raf/Erk pathway 
(39,40,41). By activating Akt, estrogen could cause phosphorylation of p27 on threonine 
157 and its subsequent cytoplasmic retention. This involvement of the estrogen activated 
Akt pathway is further supported by experiments in cells expressing dnAkt and treated 
with estrogen, which do not accumulate in the cytoplasm. Cells expressing T157Ap27 
and treated with estrogen also behave similar to estrogen treated pcDNA and  wildtype 
flag-p27 expressing cells. This result can be explained by studies showing that estrogen 
can cause rapid export of serine 10 phosphorylated p27 by the Ras/Raf/Mek/Erk pathway 
(33, 47).  
Decreased p27 levels associated with cancer are frequently caused by excessive 
proteolysis of the protein, rather than by allelic loss. Interestingly, in this study, active 
Akt, a known tumor promoter, was shown to increase p27 stability. This stabilization of 
p27 by Akt was supported by cyclohexamide experiments and 35S methionine labeling 
pulse chase experiments. It was necessary to verify the cyclohexamide data with 
methionine labeling, because cyclohexamide halts all protein synthesis in the cell, 
therefore, the decreased production of other proteins could possibly influence the 
outcome of p27 degradation. Methionine labeling allows tracking of the protein of 
interest, while other proteins are synthesized normally, providing a more physiological 
environment for experimental analysis. The importance of the stabilization of p27 by Akt 
is still undefined. It simply might be an artifact of its cellular localization. Previously 
Ishida et al (29) showed that cytoplasmic p27 is degraded at a slower rate than nuclear 
p27, and by retaining p27 in the nucleus (by mutating it on serine 10) the half-life is 
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decreased. Conversely, this stabilization of p27 could be a result of active Akt; 
stabilization of a cell cycle inhibitor in response to increased growth signals could be the 
cells attempt at decreasing proliferation, rather than a direct effect of Akt on p27. 
Interestingly, the degradation of p27 in the nucleus was not different between cells 
coexpressing flag-p27 and MryAkt, or pcDNA3 (figure 15). The cytoplasmic degradation 
of flag-p27 in control cells was less then in cells expressing MryAkt and flag-p27 
(figure14). This contrasts the results obtained with whole cell lysates, which showed 
repeatedly that MryAkt stabilized p27 protein levels. The only result in agreement with 
the whole cell lysate results is T157Ap27 and MryAkt coexpressing cells. These lysates 
showed a more stable T157Ap27 protein in the whole cell lysate, cytoplasmic, and 
nuclear fractions (figure13, 14, 15). 
The discrepancy in degradation rates of flag-p27 following  fractionation, and the 
whole cell lysate, is explained by the different distribution of p27 in the nucleus and 
cytoplasm in MryAkt transfected cells. Figure 19 shows the different percentages of p27 
in control cells or cells with active Akt.  Control cells contain more nuclear p27 than cells 
in which Akt is activated (figure 19B compare right and left panels). Cells that have 
active Akt possess more cytoplasmic p27 protein (figure 19A right panel). Therefore, in 
the whole cell lysate we are actually seeing the nuclear profile of p27 degradation in 
control cells, and the cytoplasmic profile of p27 degradation in MryAkt transfected cells 
(figure 19C). 
Figure 19: Distribution of p27 in control and MryAkt expressing 
cells (A) Proposed schematic of p27 in the cytoplasmic compartment
in control (pcDNA3) and MryAkt expressing cells. Sloping line 
indicates the rate of p27 degradation over time. % p27 protein indicates the
percentage of total p27 in that cellular compartment as a result of 
treatment(B) Graphic representation of the proposed distribution
(represented as a percentage) of p27 in the nuclear compartment in control 
and MryAkt expressing cells. (C) Graph of the distribution of p27 and it’s 
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